The March 7 meeting of the FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) for discussion of the Breo Ellipta inhaler, has been postponed due to weather. As of March 6, the meeting on GSK’s application for the fluticasone furoate/vilanterol dry powder inhaler has not been rescheduled.
Read the meeting announcement.
published on
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
October 28, 2026: Webinar: From Guidance to Practice: Navigating Revised FDA PSGs for Inhaled Products, online
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
